266 related articles for article (PubMed ID: 36057894)
1. LC-MS metabolomics of urine reveals distinct profiles for non-muscle-invasive and muscle-invasive bladder cancer.
Oto J; Fernández-Pardo Á; Roca M; Plana E; Cana F; Herranz R; Pérez-Ardavín J; Vera-Donoso CD; Martínez-Sarmiento M; Medina P
World J Urol; 2022 Oct; 40(10):2387-2398. PubMed ID: 36057894
[TBL] [Abstract][Full Text] [Related]
2. Metabolomics of Non-muscle Invasive Bladder Cancer: Biomarkers for Early Detection of Bladder Cancer.
Cheng X; Liu X; Liu X; Guo Z; Sun H; Zhang M; Ji Z; Sun W
Front Oncol; 2018; 8():494. PubMed ID: 30450336
[No Abstract] [Full Text] [Related]
3. Urine metabolomic analysis in clear cell and papillary renal cell carcinoma: A pilot study.
Oto J; Fernández-Pardo Á; Roca M; Plana E; Solmoirago MJ; Sánchez-González JV; Vera-Donoso CD; Martínez-Sarmiento M; España F; Navarro S; Medina P
J Proteomics; 2020 Apr; 218():103723. PubMed ID: 32126320
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive proteomics and platform validation of urinary biomarkers for bladder cancer diagnosis and staging.
Vanarsa K; Castillo J; Wang L; Lee KH; Pedroza C; Lotan Y; Mohan C
BMC Med; 2023 Apr; 21(1):133. PubMed ID: 37016361
[TBL] [Abstract][Full Text] [Related]
5. Targeted and untargeted urinary metabolic profiling of bladder cancer.
Ossoliński K; Ruman T; Copié V; Tripet BP; Kołodziej A; Płaza-Altamer A; Ossolińska A; Ossoliński T; Nieczaj A; Nizioł J
J Pharm Biomed Anal; 2023 Sep; 233():115473. PubMed ID: 37229797
[TBL] [Abstract][Full Text] [Related]
6. Urinary metabolomics for discovering metabolic biomarkers of bladder cancer by UPLC-MS.
Wang R; Kang H; Zhang X; Nie Q; Wang H; Wang C; Zhou S
BMC Cancer; 2022 Feb; 22(1):214. PubMed ID: 35220945
[TBL] [Abstract][Full Text] [Related]
7. Metabolic Evaluation of Urine from Patients Diagnosed with High Grade (HG) Bladder Cancer by SPME-LC-MS Method.
Łuczykowski K; Warmuzińska N; Operacz S; Stryjak I; Bogusiewicz J; Jacyna J; Wawrzyniak R; Struck-Lewicka W; Markuszewski MJ; Bojko B
Molecules; 2021 Apr; 26(8):. PubMed ID: 33920347
[TBL] [Abstract][Full Text] [Related]
8. Non-invasive diagnosis and surveillance of bladder cancer with driver and passenger DNA methylation in a prospective cohort study.
Xiao Y; Ju L; Qian K; Jin W; Wang G; Zhao Y; Jiang W; Liu N; Wu K; Peng M; Cao R; Li S; Shi H; Gong Y; Zheng H; Liu T; Luo Y; Ma H; Chang L; Li G; Cao X; Tian Y; Xu Z; Yang Z; Shan L; Guo Z; Yao D; Zhou X; Chen X; Guo Z; Liu D; Xu S; Ji C; Yu F; Hong X; Luo J; Cao H; Zhang Y; Wang X
Clin Transl Med; 2022 Aug; 12(8):e1008. PubMed ID: 35968916
[TBL] [Abstract][Full Text] [Related]
9. Value of urinary topoisomerase-IIA cell-free DNA for diagnosis of bladder cancer.
Kim YH; Yan C; Lee IS; Piao XM; Byun YJ; Jeong P; Kim WT; Yun SJ; Kim WJ
Investig Clin Urol; 2016 Mar; 57(2):106-12. PubMed ID: 26981592
[TBL] [Abstract][Full Text] [Related]
10. Profilin 1 is a potential biomarker for bladder cancer aggressiveness.
Zoidakis J; Makridakis M; Zerefos PG; Bitsika V; Esteban S; Frantzi M; Stravodimos K; Anagnou NP; Roubelakis MG; Sanchez-Carbayo M; Vlahou A
Mol Cell Proteomics; 2012 Apr; 11(4):M111.009449. PubMed ID: 22159600
[TBL] [Abstract][Full Text] [Related]
11. Untargeted urinary metabolomics for bladder cancer biomarker screening with ultrahigh-resolution mass spectrometry.
Nizioł J; Ossoliński K; Płaza-Altamer A; Kołodziej A; Ossolińska A; Ossoliński T; Nieczaj A; Ruman T
Sci Rep; 2023 Jun; 13(1):9802. PubMed ID: 37328580
[TBL] [Abstract][Full Text] [Related]
12. Diagnosis of bladder cancer and prediction of survival by urinary metabolomics.
Jin X; Yun SJ; Jeong P; Kim IY; Kim WJ; Park S
Oncotarget; 2014 Mar; 5(6):1635-45. PubMed ID: 24721970
[TBL] [Abstract][Full Text] [Related]
13. Discovery and validation of potential urinary biomarkers for bladder cancer diagnosis using a pseudotargeted GC-MS metabolomics method.
Zhou Y; Song R; Ma C; Zhou L; Liu X; Yin P; Zhang Z; Sun Y; Xu C; Lu X; Xu G
Oncotarget; 2017 Mar; 8(13):20719-20728. PubMed ID: 28157703
[TBL] [Abstract][Full Text] [Related]
14. The simultaneous use of telomerase, cytokeratin 20 and CD4 for bladder cancer detection in urine.
Siracusano S; Niccolini B; Knez R; Tiberio A; Benedetti E; Bonin S; Ciciliato S; Pappagallo GL; Belgrano E; Stanta G
Eur Urol; 2005 Mar; 47(3):327-33. PubMed ID: 15716196
[TBL] [Abstract][Full Text] [Related]
15. Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and Its Clinical Impact on the Management of High-risk Non-muscle-invasive Bladder Cancer Patients Candidate for Repeated Transurethral Resection.
Del Giudice F; Barchetti G; De Berardinis E; Pecoraro M; Salvo V; Simone G; Sciarra A; Leonardo C; Gallucci M; Catalano C; Catto JWF; Panebianco V
Eur Urol; 2020 Jan; 77(1):101-109. PubMed ID: 31699526
[TBL] [Abstract][Full Text] [Related]
16. Metabolomics analysis reveals distinct profiles of nonmuscle-invasive and muscle-invasive bladder cancer.
Sahu D; Lotan Y; Wittmann B; Neri B; Hansel DE
Cancer Med; 2017 Sep; 6(9):2106-2120. PubMed ID: 28766915
[TBL] [Abstract][Full Text] [Related]
17. UPLC-MS based urine untargeted metabolomic analyses to differentiate bladder cancer from renal cell carcinoma.
Wang Z; Liu X; Liu X; Sun H; Guo Z; Zheng G; Zhang Y; Sun W
BMC Cancer; 2019 Dec; 19(1):1195. PubMed ID: 31805976
[TBL] [Abstract][Full Text] [Related]
18. LC-MS/MS platform-based serum untargeted screening reveals the diagnostic biomarker panel and molecular mechanism of breast cancer.
Gong S; Wang Q; Huang J; Huang R; Chen S; Cheng X; Liu L; Dai X; Zhong Y; Fan C; Liao Z
Methods; 2024 Feb; 222():100-111. PubMed ID: 38228196
[TBL] [Abstract][Full Text] [Related]
19. Investigation of the urinary metabolic variations and the application in bladder cancer biomarker discovery.
Liu X; Cheng X; Liu X; He L; Zhang W; Wang Y; Sun W; Ji Z
Int J Cancer; 2018 Jul; 143(2):408-418. PubMed ID: 29451296
[TBL] [Abstract][Full Text] [Related]
20. The long noncoding RNA SUMO1P3 as urinary biomarker for monitoring bladder cancer progression.
Galbiati S; Bettiga A; Colciago G; Senti C; Trevisani F; Villa G; Marzinotto I; Ghidini M; Passalacqua R; Montorsi F; Salonia A; Vago R
Front Oncol; 2024; 14():1325157. PubMed ID: 38846969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
